In the recent years, success of the 177Lu-labeled PSMA ligand, namely, 177Lu-PSMA-617, has opened up a new chapter in the clinical management of prostate cancer, where well-established therapeutic efficacy of 177Lu in combination with targeting efficacy of the PSMA-617 ligand yielded encouraging outcomes [10–20]. Here, FOLH1 is linked to prostate cancer.